Orexo AB (publ) (STO:ORX)
Sweden
· Delayed Price · Currency is SEK 14.88
-0.86 (-5.46%)
May 2, 2025, 4:57 PM CET
Orexo AB Revenue
In the year 2024, Orexo AB had annual revenue of 590.00M SEK, down -7.64%. Orexo AB had revenue of 160.30M in the quarter ending December 31, 2024, a decrease of -3.43%.
Revenue
590.00M
Revenue Growth
-7.64%
P/S Ratio
0.92
Revenue / Employee
5.36M
Employees
110
Market Cap
543.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.00M | -48.80M | -7.64% |
| Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
| Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
| Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
| Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Medicover AB | 23.56B |
| Camurus AB | 1.87B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Bonesupport Holding AB | 997.85M |
Orexo AB News
- 22 days ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 4 months ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 4 months ago - Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology - Seeking Alpha
- 4 months ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 6 months ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire
- 6 months ago - Orexo AB reports Q3 results - Seeking Alpha
- 7 months ago - Orexo´s Nomination Committee for the Annual General Meeting 2025 - PRNewsWire
- 8 months ago - Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 - PRNewsWire